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Restenosis/re-occlusion remains a frequent complication in the ﬁrst year after percutaneous transluminal
angioplasty (PTA). In this study, association of nuclear receptor related 1 protein (Nurr1) haplotypes to
the restenosis/re-occlusion rate after femoropopliteal PTA was investigated. Patients (n ¼ 142) with
disabling claudication or critical limb ischaemia, who had undergone technically successful femo-
ropopliteal PTA, were prospectively followed up by vascular ultrasound imaging 12 months after the
procedure. Nurr1 haplotypes 2 and 3 were associated signiﬁcantly with the restenosis/re-occlusion rate
(adjusted odds ratio 1.6, 95% conﬁdence interval (CI) 1.1e2.3 and 2.0, 1.3e2.8, respectively) on univariate
analysis.
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Percutaneous transluminal angioplasty (PTA) is an established
method for treatment of peripheral artery disease. However, in up
to 50% of patients restenosis/re-occlusion remains a frequent
complication occurring in the ﬁrst year after PTA.1 Our under-
standing of the mechanisms of restenosis/re-occlusion is incom-
plete and inﬂammation is one of several factors affecting the
patency of the arterial segment after successful PTA.2 Recently,
regulation of the inﬂammation through the nuclear receptor
related 1 protein (Nurr1) has been associated with restenosis.3
Therefore, in this study the association of Nurr1 haplotypes to the
risk of restenosis/re-occlusion after femoropopliteal PTA was
investigated.Report
A total of 142 patients (58 women and 84 men aged 69  11
years) with disabling claudication or critical limb ischaemia were
enrolled after technically successful femoropopliteal PTA and were
followed up by vascular ultrasound imaging at 1, 6 and 12 months.
Adverse outcome of PTA (restenosis of 50% of the affected arterial
region or re-occlusion determined by the absence of Doppler ﬂow
signal) occurred in 85 (60%) patients. Patients with restenosis/
re-occlusion did not differ from patients with successful PTA in
risk factors or Fontaine classiﬁcation.þ386 15228070.
vski).
ciety for Vascular Surgery. PublisheDNA was extracted from blood samples and Nurr1
single-nucleotide polymorphisms SNP A (rs1466408), Nurr1 SNP B
(rs13428968) and Nurr1 SNP C (rs12803) were determined by
real-time polymerase chain reaction with appropriate primers and
TaqManprobes.Nurr1haplotypeswere reconstructed as described
earlier.3
The presence of rare alleles of Nurr1 SNP B and SNP C was
signiﬁcantly associated with restenosis/re-occlusion rate compared
with patients carrying the common alleles (hazard ratio of 1.54, 95%
conﬁdence interval (CI) 1.06e3.51 and 2.04, 95% CI 1.17e4.37,
respectively); Fig. 1.
Haplotype 1e4 frequencies were: 49.4%, 23.3%, 19.7% and
6.6%, respectively. Haplotypes 2 and 3 signiﬁcantly increased
the restenosis/re-occlusion rate (relative risks adjusted for sex,
age and Fontaine classiﬁcation calculated by Cox regression
were 1.6 (95% CI 1.1e2.3) and 2.0 (95% CI 1.3e2.8),
respectively).
Discussion
In our study restenosis/re-occlusion occurred in 85/142 (60%)
patients during the 12-month follow-up period after PTA, which
is comparable to the published data,4 and there was a signiﬁcant
association between Nurr1 haplotypes 2 and 3 and the
restenosis/re-occlusion rate, on univariate analysis. Nurr1
haplotypes have so far been associated with coronary in-stent
restenosis risk in patients undergoing percutaneous coronary
intervention.3 We were not able to conﬁrm an increased risk ofd by Elsevier Ltd. All rights reserved.
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Figure 1. KaplaneMeier survival curves for restenosis/re-occlusion rate during 12-month follow-up according to Nurr1 SNP B and SNP C genotypes (both log rank p < 0.01).
Numbers at risk at each time interval are given.
M. Bozic-Mijovski et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 337e338338restenosis/re-occlusion in patients with haplotype 4 in contrast
to the ﬁndings of Bonta et al.,3 probably due to the small
number of patients with this haplotype (<7%). However, our
results indicate that more detailed assessment of the role of
Nurr1 variants in restenosis after PTA, in larger studies, is
warranted.
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